October 10th 2025
The increasing diversity and complexity of injectable drug products is driving innovation.
Should Regulation of Combination Products Become More Centralized in Europe?
May 2nd 2013While there are those who want combination products to be controlled by a centralized pharmaceutical-type approval system, the majority of the medical technology industry wants to retain a decentralized device-focused approach.
Understanding ICH Q11—FDA's Guidance on the Development and Manufacture of Drug Substances
May 2nd 2013The author provides a review of FDA's guidance document, Guidance for Industry: Q11 Development and Manufacture of Drug Substances, and its relation to the International Conference on Harmonization's Q11 document and its application to the industry.